Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 25;19(1):74.
doi: 10.1186/s12906-019-2482-z.

In vitro evaluation of the α-glucosidase inhibitory potential of methanolic extracts of traditionally used antidiabetic plants

Astha Bhatia  1 , Balbir Singh  2 , Rohit Arora  3 , Saroj Arora  4
Affiliations

In vitro evaluation of the α-glucosidase inhibitory potential of methanolic extracts of traditionally used antidiabetic plants

Astha Bhatia et al. BMC Complement Altern Med. .

Abstract

Background: Different plant parts of Roylea cinerea (D. Don) Baill. (Lamiaceae), Clematis grata Wall. (Ranunculaceae), Cornus capitata Wall. (Cornaceae) are traditionally used in the management of diabetes and various other diseases.

Method: The air-dried plant parts from different plants were coarsely powdered and macerated in methanol to obtain their crude extracts. The crude extracts were evaluated for their α-glucosidase inhibitory activity. On the basis of results obtained, the methanolic crude extract of Cornus capitata Wall. was further sequentially fractionated in hexane, diethyl ether, ethyl acetate, n-butanol. Fractions obtained were also evaluated for their α-glucosidase inhibitory potential. The kinetic study was performed using Lineweaver Burk plot to evaluate the type of inhibition. Furthermore, in silico analysis was also carried with active sites of the enzyme (PDB ID: 3WY1) using Autodock4.

Results: Among all the plant extracts, Cornus capitata extract showed maximum inhibitory activity. Therefore its methanolic extract was further fractionated with the help of different solvents and the maximum activity was shown by the ethyl acetate fraction (IC50 50 μg/mL). Kinetic analysis indicated that Vmax and Km were increased indicating a competitive type of inhibition. In docking studies, among different constituents known in this plant, betulinic acid showed minimum binding energy (- 10.21 kcal/mol). The kinetic and docking studies have strengthened the observation made in the present study regarding the α-glucosidase inhibitory activity of Cornus capitata.

Conclusion: The study provided partial evidence for pharmacological basis regarding clinical applications of Cornus capitata in the treatment of diabetes suggesting it to be a suitable candidate for the treatment of postprandial hyperglycemia.

Keywords: Clematis grata wall.; Cornus capitata wall.; Roylea cinerea (D. Don) Baill; α-Glucosidase.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Protein structure of homologue of α-glucosidase obtained from RCSB protein data bank for docking a. Structure of 3WY1 protein (chain a and b); b. Binding pocket showing binding with ligands
Fig. 2
Fig. 2
Comparative representation of α-glucosidase inhibitory activity (% Inhibition by plant extracts and standard Acarbose)
Fig. 3
Fig. 3
Lineweaver-Burk plot of the reaction of yeast α-glucosidase in the presence of inhibitor methanolic extract of Cornus capitata leaves extract
Fig. 4
Fig. 4
Docking conformations (Chimaera software) showing interaction (residue-ligand H-bonds green coloured) of a) Arjunolic acid b) Betulin c) Betulinic acid d) Epibetulin e) Lupeol f) Maslinic acid with binding site of α-glucosidase
See this image and copyright information in PMC

References

    1. Joshi SR, Standl E, Tong N, Shah P, Kalra S, Rathod R. Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. Expert Opin Pharmacother. 2015;16(13):1959–1981. doi: 10.1517/14656566.2015.1070827. - DOI - PubMed
    1. AG HB Pharmacology of α-glucosidase inhibition. Eur J Clin Investig. 1994;S3:3–10. - PubMed
    1. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Libr. 2006;4:CD005061-CD005061. - PubMed
    1. DiNicolantonio JJ, Bhutani J, O'Keefe JH. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open heart. 2015;2(1):e000327. doi: 10.1136/openhrt-2015-000327. - DOI - PMC - PubMed
    1. Kapoor LD. Handbook of Ayurvedic medicinal plants: herbal reference library. Newyork: Routledge; 2017.

MeSH terms